| 复方甘草酸苷治疗新型冠状病毒肺炎的可行性分析 |
| |
| 引用本文： | 杨磊,刘佳琦,边原,陈岷,童荣生,唐俊晖,范玉婷,蔡璐璐. 复方甘草酸苷治疗新型冠状病毒肺炎的可行性分析[J]. 华西药学杂志, 2020, 35(3): 342-346. DOI: 10.13375/j.cnki.wcjps.2020.03.021 |
| |
| 作者姓名： | 杨磊 刘佳琦 边原 陈岷 童荣生 唐俊晖 范玉婷 蔡璐璐 |
| |
| 作者单位： | 电子科技大学医学院,四川成都610054;电子科技大学医学院,四川成都610054;四川省医学科学院·四川省人民医院药学部个体化药物治疗四川省重点实验室,四川成都610072;成都医学院,四川成都610500 |
| |
| 基金项目： | 四川省中医药管理局研究基金;应对新型冠状病毒科技攻关应急项目;四川省科学技术厅重点研究发展计划 |
| |
| 摘 要： | 临床上大都采用对症治疗的方式治疗新型冠状病毒肺炎(COVID-19),对于新型冠状病毒尚无特效抑制药物。现通过对既往复方甘草酸苷用于严重急性呼吸综合征(SARS)治疗的有效性和安全性的总结,以期为复方甘草酸苷抗击新型冠状病毒肺炎提供理论依据。
|
| 关 键 词： | 新型冠状病毒肺炎 新型冠状病毒 严重急性呼吸综合征 甘草酸苷 抗病毒 可行性分析 |
Feasibility analysis of Compounds glycyrrhizin in the treatment of COVID-19 |
| |
| YANG Lei,LIU Jiaqi,BIAN Yuan,CHEN Min,TONG Rongsheng,TANG Junhui,FAN Yuting,CAI Lulu. Feasibility analysis of Compounds glycyrrhizin in the treatment of COVID-19[J]. West China Journal of Pharmaceutical Sciences, 2020, 35(3): 342-346. DOI: 10.13375/j.cnki.wcjps.2020.03.021 |
| |
| Authors: | YANG Lei LIU Jiaqi BIAN Yuan CHEN Min TONG Rongsheng TANG Junhui FAN Yuting CAI Lulu |
| |
| Affiliation: | (School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,610054 P.R.China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu,Sichuan,610072 P.R.China;Chengdu Medical College,Chengdu,Sichuan,610500 P.R.China) |
| |
| Abstract: | At present,symptomatic treatment is mostly used in the clinic,and there is no effective inhibitory drug for COVID-19.Therefore,it is an important task to provide alternative drug,which is safe and effective in the clinical.We summarized the effectiveness and safety of reciprocating glycyrrhizin in the treatment of severe acute respiratory syndrome,in order to provide theoretical evidence for compound glycyrrhizin to resist COVID-19. |
| |
| Keywords: | COVID-19 SARS-CoV-2 Severe acute respiratory syndrome Glycyrrhizin Antivirus Feasibility analysis |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
